Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05819814 · ClinicalTrials.gov registry record · NA

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health

A NA study of Coronary Artery Disease, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT05819814: Recruiting NA study of Coronary Artery Disease, sponsored by Massachusetts General Hospital.

NCT05819814 is a NA study of Coronary Artery Disease that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 200 participants, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05819814, a NA study of Coronary Artery Disease, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The goal of this randomized controlled trial is to assess the impact of disclosing a high polygenic risk result for coronary artery disease on change in cardiovascular health over one year.

Primary Outcome

Change in cardiovascular health from baseline to one year as measured by the American Heart Association's Life's Essential 8 (LE8) Score will be compared between an intervention arm that receives a high polygenic risk result for coronary artery disease and a control group that receives standard of care. The LE8 score ranges between 0 and 100 with higher numbers indicating better cardiovascular health.

Conditions Studied

Interventions

  • BEHAVIORAL Disclosure of high polygenic risk result for coronary artery disease

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2023-12-07
Est. Completion 2027-05-01
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT05819814 shows while recruiting

NCT05819814 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,286-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (84% lower).

The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Disclosure of high polygenic risk result for coronary artery disease is the first listed.

NCT05819814 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05819814 about?

NCT05819814 is a clinical study titled "Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health". The goal of this randomized controlled trial is to assess the impact of disclosing a high polygenic risk result for coronary artery disease on change in cardiovascular health over one year.

What is the current status of trial NCT05819814?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2023-12-07. Estimated completion is 2027-05-01.

What conditions does trial NCT05819814 study?

This clinical trial studies the following conditions: Coronary Artery Disease.

What interventions are being tested in trial NCT05819814?

The interventions under investigation include: Disclosure of high polygenic risk result for coronary artery disease (BEHAVIORAL).

Who is sponsoring clinical trial NCT05819814?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05819814 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05819814's enrollment target sits among peer trials

200 117th of 219 higher than 100 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05819814, the US trial registry maintained by the National Library of Medicine. NCT05819814 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.